RESEARCH TRIANGLE PARK, N.C., May 1, 2016 /PRNewswire/ -- Envisia Therapeutics today announced that eight posters have been selected for presentation at the Association for Research in Vision and Ophthalmology's (ARVO) Annual Meeting being held May 1 – 5, 2016 in Seattle, WA. ARVO is the largest gathering of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75 countries. The theme of the ARVO 2016 Annual Meeting is Research: A vision for hope.
"ARVO continues to be the preeminent venue for scientific exchange in ophthalmology and we are very pleased to be able to present a comprehensive array of data from our pipeline programs," said Benjamin Yerxa, PhD, President of Envisia Therapeutics. "We are incredibly proud of the progress we have made and welcome the opportunity to showcase that progress at this world renowned meeting."
Details related to Envisia presentations at ARVO are as follows:
Sunday, May 1, 2016
Poster #A0164: Extended Release of anti-VEGF Biologics from Biodegradable Hydrogel Implants for the Treatment of Age Related Macular Degeneration
Poster #A0374: Completed 28-Day and Ongoing 12-Month Safety and Efficacy Evaluation of ENV515 (travoprost) Intracameral Implant in Phase 2 Study
Poster #A0099: A 6-Week Ocular Pharmacokinetic Study of ENV905 (difluprednate) Intracameral Implant or Durezol in the Albino Rabbit
Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.
Advertisement
"ARVO continues to be the preeminent venue for scientific exchange in ophthalmology and we are very pleased to be able to present a comprehensive array of data from our pipeline programs," said Benjamin Yerxa, PhD, President of Envisia Therapeutics. "We are incredibly proud of the progress we have made and welcome the opportunity to showcase that progress at this world renowned meeting."
Advertisement
Details related to Envisia presentations at ARVO are as follows:
Sunday, May 1, 2016
Poster #A0164: Extended Release of anti-VEGF Biologics from Biodegradable Hydrogel Implants for the Treatment of Age Related Macular Degeneration
- Exhibit Hall, AMD and Anti-VEGF Therapy, 1:30pm – 3:15pm, Sunday, May 1, 2016
- Presented by Gary Owens, MS – Principal Scientist, Analytical Sciences
Poster #A0374: Completed 28-Day and Ongoing 12-Month Safety and Efficacy Evaluation of ENV515 (travoprost) Intracameral Implant in Phase 2 Study
- Exhibit Hall, Glaucoma Clinical Studies/Pharmacology, 8:30am - 10:15am, Tuesday, May 3, 2016
- Presented by Dr. Thomas R. Walters, MD – Texan Eye/Keystone Research, Austin TX
- Exhibit Hall, Glaucoma Clinical Studies/Pharmacology, 8:30am - 10:15am, Tuesday, May 3, 2016
- Presented by Tomas Navratil, PhD – Senior Vice President, Development
- Exhibit Hall, Diabetic Retinopathy and Steroids, 8:30am - 10:15am, Tuesday, May 3, 2016
- Presented by Sanjib K. Das, PhD – Sr. Principal Scientist, Research
- Exhibit Hall, Drug Delivery, 3:45pm – 5:30pm Tuesday, May 3, 2016
- Presented by RiLee Robeson – Manager, Nonclinical Development
- Exhibit Hall, Drug Delivery, 3:45pm - 5:30pm, Tuesday, May 3, 2016
- Presented by Melissa Sandahl , MS – Scientist, Research
- Exhibit Hall, Drug Delivery, 3:45pm – 5:30pm, Tuesday, May 3, 2016
- Presented by Janet Tully – Senior Scientist, Analytical
Poster #A0099: A 6-Week Ocular Pharmacokinetic Study of ENV905 (difluprednate) Intracameral Implant or Durezol in the Albino Rabbit
- Exhibit Hall, Cornea Disease Therapy, 8:00am – 9:45am, Thursday, May 5, 2016
- Presented by Rozemarijn Verhoeven, MS – Executive Director, Nonclinical Development
Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/envisia-therapeutics-to-present-at-arvo-2016-annual-meeting-300260562.html
SOURCE Envisia Therapeutics